NRAS

Summary

Gene Symbol: NRAS
Description: NRAS proto-oncogene, GTPase
Alias: ALPS4, CMNS, N-ras, NCMS, NRAS1, NS6, GTPase NRas, N-ras protein part 4, neuroblastoma RAS viral (v-ras) oncogene homolog, neuroblastoma RAS viral oncogene homolog, transforming protein N-Ras, v-ras neuroblastoma RAS viral oncogene homolog
Species: human

Top Publications

  1. pmc Characterization of c-Ki-ras and N-ras oncogenes in aflatoxin B1-induced rat liver tumors
    G McMahon
    Division of Toxicology, Whitaker College, Cambridge, MA
    Proc Natl Acad Sci U S A 87:1104-8. 1990
  2. ncbi Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines
    E J Bernhard
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia 19104 6072, USA
    Cancer Res 60:6597-600. 2000
  3. ncbi Near reflex accommodation spasm: unusual presentation of generalized photosensitive epilepsy
    Eli Shahar
    Child Neurology Unit and Epilepsy Service, Rambam Medical Center, Rappaport School of Medicine, Haifa, Israel
    J Clin Neurosci 9:605-7. 2002
  4. ncbi Activated Ras induces lens epithelial cell hyperplasia but not premature differentiation
    Lixing W Reneker
    Department of Ophthalmology, School of Medicine, University of Missouri, Columbia, Missouri, USA
    Int J Dev Biol 48:879-88. 2004
  5. doi WHO Working Group on revision of the Manual of Laboratory Methods for Testing DTP Vaccines-Report of two meetings held on 20-21 July 2006 and 28-30 March 2007, Geneva, Switzerland
    Michael J Corbel
    National Institute for Biological Standards and Control, UK
    Vaccine 26:1913-21. 2008
  6. ncbi The complexity of Raf-1 regulation
    D K Morrison
    Molecular Basis of Carcinogenesis Laboratory, ABL Basic Research Program, National Cancer Institute, Frederick Cancer Research and Development Center, Frederick, MD 21702, USA
    Curr Opin Cell Biol 9:174-9. 1997
  7. doi HIV-1 Nef compensates for disorganization of the immunological synapse by inducing trans-Golgi network-associated Lck signaling
    Xiaoyu Pan
    Department of Infectious Diseases, Virology, University Hospital Heidelberg, Germany
    Blood 119:786-97. 2012
  8. pmc Caveolin-1 regulates human immunodeficiency virus-1 Tat-induced alterations of tight junction protein expression via modulation of the Ras signaling
    Yu Zhong
    Molecular Neuroscience and Vascular Biology Laboratory, Department of Neurosurgery, University of Kentucky, Lexington, Kentucky 40536, USA
    J Neurosci 28:7788-96. 2008
  9. ncbi Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma
    M E Pacold
    MRC Laboratory of Molecular Biology Hills Road CB2 2QH, Cambridge, United Kingdom
    Cell 103:931-43. 2000
  10. ncbi Prognostic significance of N-RAS and K-RAS mutations in 232 patients with acute myeloid leukemia
    Markus Ritter
    Haematologica 89:1397-9. 2004

Research Grants

  1. Rutao Cui; Fiscal Year: 2014
  2. The Unfolded Protein Response in Melanoma Progression and Chemoresistance
    Maria S Soengas; Fiscal Year: 2012
  3. Jeffrey W Smith; Fiscal Year: 2016
  4. DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE LEUKEMIA
    Jerry Radich; Fiscal Year: 1993
  5. Genetic and genomic analysis of Ras signaling in colorectal cancer progression
    KEVIN MICHAEL HAIGIS; Fiscal Year: 2010
  6. BONNIE ELYSSA GOULDROTHBERG; Fiscal Year: 2014
  7. Compartment Specific Signaling of Ras
    MARK REID PHILIPS; Fiscal Year: 2010
  8. Sheri L Holmen; Fiscal Year: 2016
  9. TRANSCRIPTIONAL INTERFERENCE AND TUMORIGENICITY
    Perry Kannan; Fiscal Year: 2000
  10. Preeti Tandon; Fiscal Year: 2014

Detail Information

Publications267 found, 100 shown here

  1. pmc Characterization of c-Ki-ras and N-ras oncogenes in aflatoxin B1-induced rat liver tumors
    G McMahon
    Division of Toxicology, Whitaker College, Cambridge, MA
    Proc Natl Acad Sci U S A 87:1104-8. 1990
    ..The presence of a potential germ-line oncogene may be related to the sensitivity of the Fischer rat strain to liver carcinogenesis by aflatoxin B1 and other chemical carcinogens...
  2. ncbi Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines
    E J Bernhard
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia 19104 6072, USA
    Cancer Res 60:6597-600. 2000
    ..These findings support the development of strategies that target ras for inactivation in the treatment of cancer...
  3. ncbi Near reflex accommodation spasm: unusual presentation of generalized photosensitive epilepsy
    Eli Shahar
    Child Neurology Unit and Epilepsy Service, Rambam Medical Center, Rappaport School of Medicine, Haifa, Israel
    J Clin Neurosci 9:605-7. 2002
    We report on a 9 year old girl admitted with prolonged and recurrent episodes of near reflex accommodation spasm (NRAS), which was the sole clinical manifestation of primary generalized photosensitive epilepsy...
  4. ncbi Activated Ras induces lens epithelial cell hyperplasia but not premature differentiation
    Lixing W Reneker
    Department of Ophthalmology, School of Medicine, University of Missouri, Columbia, Missouri, USA
    Int J Dev Biol 48:879-88. 2004
    ..Expression of activated Ras was sufficient to stimulate lens cell proliferation but not differentiation, implying that alternative or additional signal transduction pathways are required to induce fiber cell differentiation...
  5. doi WHO Working Group on revision of the Manual of Laboratory Methods for Testing DTP Vaccines-Report of two meetings held on 20-21 July 2006 and 28-30 March 2007, Geneva, Switzerland
    Michael J Corbel
    National Institute for Biological Standards and Control, UK
    Vaccine 26:1913-21. 2008
    This report reflects the discussion and conclusions of a WHO group of experts from National Regulatory Authorities (NRAs), National Control Laboratories (NCLs), vaccine industries and other relevant institutions involved in ..
  6. ncbi The complexity of Raf-1 regulation
    D K Morrison
    Molecular Basis of Carcinogenesis Laboratory, ABL Basic Research Program, National Cancer Institute, Frederick Cancer Research and Development Center, Frederick, MD 21702, USA
    Curr Opin Cell Biol 9:174-9. 1997
    ..The picture clearly emerging is that Raf-1 activity can be regulated by multiple mechanisms...
  7. doi HIV-1 Nef compensates for disorganization of the immunological synapse by inducing trans-Golgi network-associated Lck signaling
    Xiaoyu Pan
    Department of Infectious Diseases, Virology, University Hospital Heidelberg, Germany
    Blood 119:786-97. 2012
    ..Nef therefore hijacks Lck sorting to selectively activate TGN-associated arms of compartmentalized TCR signaling. By tailoring T-lymphocyte responses to antigenic stimulation, Nef optimizes the environment for HIV-1 replication...
  8. pmc Caveolin-1 regulates human immunodeficiency virus-1 Tat-induced alterations of tight junction protein expression via modulation of the Ras signaling
    Yu Zhong
    Molecular Neuroscience and Vascular Biology Laboratory, Department of Neurosurgery, University of Kentucky, Lexington, Kentucky 40536, USA
    J Neurosci 28:7788-96. 2008
    ..Thus, caveolin-1 may provide an effective target to protect against Tat-induced HBMEC dysfunction and the disruption of the BBB in HIV-1-infected patients...
  9. ncbi Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma
    M E Pacold
    MRC Laboratory of Molecular Biology Hills Road CB2 2QH, Cambridge, United Kingdom
    Cell 103:931-43. 2000
    ..These unique Ras/PI3Kgamma interactions are likely to be shared by PI3Kalpha. The complex with Ras shows a change in the PI3K conformation that may represent an allosteric component of Ras activation...
  10. ncbi Prognostic significance of N-RAS and K-RAS mutations in 232 patients with acute myeloid leukemia
    Markus Ritter
    Haematologica 89:1397-9. 2004
    ..A peptide nucleic acid (PNA)-based technique was used on 232 AML samples to detect point mutations of the hotspots in N-RAS and K-RAS. No significant correlations between RAS mutations and clinical features, karyotype or FLT3 were found...
  11. pmc Pathway- and expression level-dependent effects of oncogenic N-Ras: p27(Kip1) mislocalization by the Ral-GEF pathway and Erk-mediated interference with Smad signaling
    Shiri Kfir
    Department of Neurobiochemistry, The George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel
    Mol Cell Biol 25:8239-50. 2005
    ..These findings have important implications for the contribution of activated Ras to oncogenesis and for the conversion of TGF-beta from an inhibitory to a metastatic factor in some epithelial tumors...
  12. ncbi BRAF and NRAS mutations in melanoma and melanocytic nevi
    Jenny N Poynter
    Department of Epidemiology, University of Michigan, Ann Arbor, Michigan 48109 2200, USA
    Melanoma Res 16:267-73. 2006
    In this report, we investigated BRAF/NRAS mutations in samples from a case-control study of melanoma and a series of benign melanocytic nevi...
  13. pmc Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations
    Martin Zenker
    Institute of Human Genetics, University of Erlangen Nuremberg, Germany
    J Med Genet 44:131-5. 2007
    ..Germline mutations in KRAS have recently been identified in a small number of patients with Noonan syndrome and CFC...
  14. ncbi NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing
    Esther Edlundh-Rose
    Department of Gene Technology, School of Biotechnology, Royal Institute of Technology KTH, AlbaNova University Center, Stockholm, Sweden
    Melanoma Res 16:471-8. 2006
    We have previously demonstrated the use of pyrosequencing to investigate NRAS [neuroblastoma RAS viral (v-ras) oncogene homolog] mutations in melanoma biopsies...
  15. doi Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
    Richard F Schlenk
    University Hospital of Ulm, Ulm, Germany
    N Engl J Med 358:1909-18. 2008
    ..binding protein alpha gene (CEPBA), the myeloid-lymphoid or mixed-lineage leukemia gene (MLL), and the neuroblastoma RAS viral oncogene homolog (NRAS). We evaluated the associations of these mutations with clinical outcomes in patients.
  16. doi KIT gene mutations and copy number in melanoma subtypes
    Carol Beadling
    Oregon Cancer Institute, Oregon Health and Science University, Portland, Oregon 97239, USA
    Clin Cancer Res 14:6821-8. 2008
    ..To determine the frequency of KIT mutations across melanoma subtypes, we surveyed a large series of tumors...
  17. pmc Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma
    Victoria R Greene
    The Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Invest Dermatol 129:1483-8. 2009
    A lack of consensus exists with regards to the relative rates of NRAS and BRAF mutations in the radial (RGP) and vertical (VGP) growth phases of individual melanoma tumors...
  18. doi Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site
    Anton Platz
    Department of Oncology Pathology, Karolinska Institute, Cancer Centre Karolinska, Karolinska University Hospital Solna, Stockholm S 17176, Sweden
    Mol Oncol 1:395-405. 2008
    A majority of cutaneous melanomas show activating mutations in the NRAS or BRAF proto-oncogenes, components of the Ras-Raf-Mek-Erk signal transduction pathway...
  19. pmc Oncogenic NRAS cooperates with p53 loss to generate melanoma in zebrafish
    Michael Dovey
    Stem Cell Program and Hematology Oncology, Children s Hospital, Boston, Massachusetts, USA
    Zebrafish 6:397-404. 2009
    b>NRAS mutations are a common oncogenic event in skin cancer, occurring frequently in congenital nevi and malignant melanoma...
  20. pmc A restricted spectrum of NRAS mutations causes Noonan syndrome
    Ion C Cirstea
    Institute of Biochemistry and Molecular Biology II, Heinrich Heine University Medical Center, Dusseldorf, Germany
    Nat Genet 42:27-9. 2010
    ..Here we report that germline NRAS mutations conferring enhanced stimulus-dependent MAPK activation account for some cases of this disorder...
  21. pmc Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes
    Irene Lurkin
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, Rotterdam, The Netherlands
    PLoS ONE 5:e8802. 2010
    ..We developed two multiplex assays that simultaneously screen 22 nucleotides in the KRAS, NRAS, BRAF and PIK3CA genes for mutations...
  22. doi Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
    Wendy De Roock
    Centre for Human Genetics, KU Leuven, Leuven, Belgium
    Lancet Oncol 11:753-62. 2010
    ....
  23. pmc NRAS mutations are rare in colorectal cancer
    Natsumi Irahara
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Diagn Mol Pathol 19:157-63. 2010
    Activating mutations in members of the RAS oncogene family (KRAS, HRAS, and NRAS) have been found in a variety of human malignancies, suggesting a dominant role in carcinogenesis...
  24. pmc Clinical correlates of NRAS and BRAF mutations in primary human melanoma
    Julie A Ellerhorst
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 17:229-35. 2011
    b>NRAS and BRAF mutations are common in cutaneous melanomas, although rarely detected mutually in the same tumor...
  25. doi Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis
    J H Lee
    Department of Pathology, Korea University Ansan Hospital, 516, Gojan 1 dong, Danwon gu, Ansan si, Gyeonggi do 425 707, Korea
    Br J Dermatol 164:776-84. 2011
    There have been conflicting data regarding the prevalence and clinicopathological characteristics of BRAF and NRAS mutations in primary cutaneous melanoma.
  26. pmc N-Ras(G12D) induces features of stepwise transformation in preleukemic human umbilical cord blood cultures expressing the AML1-ETO fusion gene
    Fu Sheng Chou
    Division of Experimental Hematology and Cancer Biology, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA
    Blood 117:2237-40. 2011
    ..N-Ras(G12D) promotes progression toward transformation in AE-expressing cells, partially through up-regulating Bcl-2...
  27. pmc Noonan syndrome gain-of-function mutations in NRAS cause zebrafish gastrulation defects
    Vincent Runtuwene
    Hubrecht Institute KNAW and University Medical Center Utrecht, Uppsalalaan 8, 3584 CT Utrecht, The Netherlands
    Dis Model Mech 4:393-9. 2011
    ..Recently, two mutations in NRAS were reported to be associated with Noonan syndrome, T50I and G60E...
  28. doi Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer
    Cecily P Vaughn
    ARUP Institute for Clinical and Experimental Pathology, 500 Chipeta Way, Salt Lake City, UT 84108, USA
    Genes Chromosomes Cancer 50:307-12. 2011
    ..12 and 13, were tested for mutations in codons 61 and 146 of KRAS, codon 600 of BRAF, and codons 12, 13, and 61 of NRAS. Mutation status was determined by targeted pyrosequencing...
  29. doi Lack of BRAF(V600E) mutations in giant congenital melanocytic nevi in a Chinese population
    Di Wu
    Department of Cleft Lip and Palate, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China
    Am J Dermatopathol 33:341-4. 2011
    ..mutation frequencies of BRAF(V600E) (V-raf murine sarcoma virus oncogene homolog B1) and NRAS (neuroblastoma ras viral oncogene homolog) codon 61 in CMNs of Chinese, we selected 55 paraffin-embedded tissue blocks, including 37 cases ..
  30. pmc NRAS mutation status is an independent prognostic factor in metastatic melanoma
    John A Jakob
    Department of Melanoma Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 118:4014-23. 2012
    ..tested the prognostic significance and clinicopathologic correlations of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) and neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) mutations in patients with metastatic melanoma.
  31. doi BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma
    Maria Colombino
    Istituto Chimica Biomolecolare, Consiglio Nazionaledelle Ricerche, Italy
    J Clin Oncol 30:2522-9. 2012
    The prevalence of BRAF, NRAS, and p16CDKN2A mutations during melanoma progression remains inconclusive. We investigated the prevalence and distribution of mutations in these genes in different melanoma tissues.
  32. pmc Novel somatic mutations to PI3K pathway genes in metastatic melanoma
    Austin Y Shull
    Georgia Health Sciences University Cancer Center, Georgia Health Sciences University, Augusta, Georgia, United States of America
    PLoS ONE 7:e43369. 2012
    ..We hypothesized that somatic mutations in the Phosphoinositide 3-Kinase (PI3K) pathway, which promotes proliferation and survival, may coincide with BRAF(V600) mutations and contribute to chemotherapeutic resistance...
  33. doi BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma
    Graham J Mann
    The University of Sydney at Westmead Millennium Institute, Westmead, New South Wales, Australia
    J Invest Dermatol 133:509-17. 2013
    ..0) or low pigmentation (3.0, 0.8-100.0) in the nodal metastases. Absence of BRAF mutation (20.0, 1.0-1000.0) or NRAS mutation (16.7, 0.6-1000.0) were both favorable prognostic factors...
  34. pmc Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
    Lawrence N Kwong
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Nat Med 18:1503-10. 2012
    ..inhibitors of the BRAF proto-oncogene has revolutionized therapy for melanoma harboring mutations in BRAF, yet NRAS-mutant melanoma remains without an effective therapy...
  35. pmc Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma
    Einar Birkeland
    Section of Oncology, Institute of Medicine, University of Bergen, Bergen, Norway
    Clin Exp Metastasis 30:867-76. 2013
    ..In this single institution study, we correlated mutation status and expression levels of BRAF and NRAS to dacarbazine (DTIC) treatment response as well as progression-free and overall survival in a cohort of 85 ..
  36. pmc Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
    Maria Colombino
    Unit of Cancer Genetics, Institute of Biomolecular Chemistry ICB, National Research Council CNR, Traversa La Crucca 3, Baldinca Li Punti 07100, Sassari, Italy
    J Transl Med 11:202. 2013
    Prevalence and distribution of pathogenetic mutations in BRAF and NRAS genes were evaluated in multiple melanoma lesions from patients with different geographical origin within the same Italian population.
  37. pmc RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases
    Jean Nicolas Vauthey
    Departments of Surgical Oncology Gastrointestinal Medical Oncology Hematopathology Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX
    Ann Surg 258:619-26; discussion 626-7. 2013
    ..To determine the impact of RAS mutation status on survival and patterns of recurrence in patients undergoing curative resection of colorectal liver metastases (CLM) after preoperative modern chemotherapy...
  38. doi Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
    Jean Yves Douillard
    Institut de Cancérologie de l Ouest ICO René Gauducheau, Nantes, France
    N Engl J Med 369:1023-34. 2013
    ..Other activating RAS mutations may also be negative predictive biomarkers for anti-EGFR therapy...
  39. ncbi NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression
    Katarina Omholt
    Cancer Centre Karolinska, Department of Oncology Pathology, Radiumhemmet, Karolinska Hospital and Institute, Stockholm, Sweden
    Clin Cancer Res 9:6483-8. 2003
    ..Previously, we analyzed a large series of paired primary and metastatic melanomas for NRAS codon 61 mutations and showed that they arise early and are preserved during tumor progression...
  40. ncbi BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival
    Lars A Akslen
    The Gade Institute, Section of Pathology, University of Bergen, Haukeland University Hospital, Bergen, Norway
    J Invest Dermatol 125:312-7. 2005
    Previous studies have shown frequent mutations in the BRAF (V-raf murine sarcoma viral oncogene homolog B1) or NRAS (neuroblastoma RAS viral [V-ras] oncogene homolog) genes in cutaneous melanoma, but the relationship between these ..
  41. ncbi Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma
    M Sensi
    Human Tumor Immunobiology Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
    Oncogene 25:3357-64. 2006
    Activating BRAF or NRAS mutations have been found in 80% of human sporadic melanomas, but only one of these genetic alterations could be detected in each tumour...
  42. ncbi Frequency of RAS gene mutation and its cooperative genetic events in Southeast Asian adult acute myeloid leukemia
    Chirayu U Auewarakul
    Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
    Eur J Haematol 77:51-6. 2006
    ..Several additional genetic abnormalities occurred in RAS-mutated patients. Future molecular-targeting approaches should take into account the multiple genetic events that coexist with RAS mutations in AML patients...
  43. pmc NRAS mutation causes a human autoimmune lymphoproliferative syndrome
    Joao B Oliveira
    Department of Laboratory Medicine, Clinical Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 104:8953-8. 2007
    The p21 RAS subfamily of small GTPases, including KRAS, HRAS, and NRAS, regulates cell proliferation, cytoskeletal organization, and other signaling networks, and is the most frequent target of activating mutations in cancer...
  44. doi Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia
    Yuichi Ishikawa
    Department of Infectious Diseases, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Eur J Haematol 83:90-8. 2009
    ..These results collectively suggest that TP53 mutation might be a functionally distinguishable class of mutation...
  45. doi Somatic mosaicism for oncogenic NRAS mutations in juvenile myelomonocytic leukemia
    Sayoko Doisaki
    Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan
    Blood 120:1485-8. 2012
    ..Somatic mutations in genes involved in GM-CSF signal transduction, such as NRAS, KRAS, PTPN11, NF1, and CBL, have been identified in more than 70% of children with JMML...
  46. ncbi Ras oncogene activation in benign and malignant colorectal tumours
    D A Spandidos
    Institute of Biological Research and Biotechnology, National Hellenic Research Foundation, Athens, Greece
    Tumori 81:7-11. 1995
    ....
  47. pmc MGSA/GRO-mediated melanocyte transformation involves induction of Ras expression
    D Wang
    Department of Cell Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Oncogene 19:4647-59. 2000
    ..These data suggest that MGSA/GRO-mediated transformation requires Ras activation in melanocytes...
  48. ncbi [Abnormalities of the p53, N-ras, DCC and FLT-3 genes in myelodysplastic syndromes]
    K Nakamura
    Department of 3rd Internal Medicine, Nippon Medical School, Tokyo, Japan
    J Nippon Med Sch 68:143-8. 2001
    ..Abnormalities of p53 and DCC genes were significantly associated with survival time (p< 0.02, p< 0.004, respectively)...
  49. ncbi Partial functional overlap of the three ras genes in mouse embryonic development
    K Nakamura
    Mouse Genome Technology Laboratory, Mitsubishi Kagaku Institute of Life Sciences, Machida, Tokyo, Japan
    Oncogene 27:2961-8. 2008
    ..5 and E15.5 was more intense in major organs, including the heart, than those of endogenous ras genes. We therefore conclude that the functions of the ras genes are partially overlapping in mouse embryonic development...
  50. pmc Oncogenicity of human N-ras oncogene and proto-oncogene introduced into retroviral vectors
    M Souyri
    Laboratoire d Immunologie et Oncologie des Maladies Rétrovirales, Hopital Cochin, INSERM U152, CNRS UA628, Paris, France
    J Virol 63:3944-53. 1989
    ..Altogether, these data demonstrated unequivocally that N-ras is potentially as oncogenic as H-ras and that such oncogenic effect could depend on the vector environment...
  51. ncbi Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma
    A Demunter
    Department of Pathology, Laboratory of Morphology and Molecular Pathology, University Hospitals, Katholieke Universiteit Leuven, Leuven, Belgium
    J Invest Dermatol 117:1483-9. 2001
    ....
  52. ncbi c-N-ras is activated infrequently in canine malignant lymphoma
    M D Edwards
    Department of Surgery, School of Veterinary Medicine, University of California, Davis 95616 8745
    Toxicol Pathol 21:288-91. 1993
    ..The results of this study demonstrate that, similar to the human, c-N-ras mutations are uncommon in dogs with malignant lymphoma and that there is no association between 2,4-D exposure and activation of c-N-ras in the dog...
  53. ncbi Parental exposure to medications and hydrocarbons and ras mutations in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group
    Xiao Ou Shu
    Vanderbilt Ingram Cancer Center and Vanderbilt Center for Health Services Research, Vanderbilt University, Nashville, Tennessee, USA
    Cancer Epidemiol Biomarkers Prev 13:1230-5. 2004
    ..8, 95% CI 1.0-1.3) were associated with N-ras mutations. This study suggests that parental exposure to specific chemicals may be associated with distinct ras mutations in children who develop ALL...
  54. ncbi Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro
    D W End
    Department of Oncology, Janssen Research Foundation, Spring House, Pennsylvania 19477, USA
    Cancer Res 61:131-7. 2001
    ....
  55. pmc Inhibition of the proprotein convertases represses the invasiveness of human primary melanoma cells with altered p53, CDKN2A and N-Ras genes
    Claude Lalou
    INSERM, UMRS940, Equipe Avenir, Institut de Genetique Moleculaire, Hopital Saint Louis, Universite Paris 7, Paris, France
    PLoS ONE 5:e9992. 2010
    ..These alterations were found to be responsible for acquisition of invasive and metastatic potential through their defective regulatory control of metalloproteinases and urokinase genes...
  56. ncbi Activation of the Ha-, Ki-, and N-ras genes in chemically induced liver tumors from CD-1 mice
    S Manam
    Department of Safety Assessment, Merck Sharp and Dohme Research Laboratories, West Point, Pennsylvania 19486
    Cancer Res 52:3347-52. 1992
    ....
  57. pmc Mutations in PIK3CA are infrequent in neuroblastoma
    Vincent Dam
    Division of Oncology, The Children s Hospital of Philadelphia Philadelphia, PA, USA
    BMC Cancer 6:177. 2006
    ..In this murine model we additionally surveyed for Ras family and Braf mutations as these have not been previously reported...
  58. pmc P19 H-ras induces G1/S phase delay maintaining cells in a reversible quiescence state
    Maria Camats
    Unidad de Splicing, Instituto de Investigaciones Biomédicas de Barcelona Consejo Superior de Investigaciones Científicas, Barcelona, Spain
    PLoS ONE 4:e8513. 2009
    ..This observation suggests that p19 and p21 play differential and complementary roles in the cell...
  59. ncbi ras and c-myc oncoproteins during tumor progression in the uterine cervix
    S A Nair
    Division of Laboratory Medicine, Regional Cancer Centre, Thiruvananthapuram, Kerala State, India
    Tumori 84:583-8. 1998
    ..8856, P=0.001) and various histological stages of tumor progression in the cervical epithelium. CONCLUSIONS: These results therefore suggest that c-myc and N-ras oncoproteins are important during tumor progression in the uterine cervix...
  60. ncbi Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9
    Rajiv Kumar
    Division of Molecular Genetic Epidemiology, German Cancer Research Center DKFZ, Im Neuenheimer Feld 580, Heidelberg 69210, Germany
    Oncogene 22:9217-24. 2003
    ..38+/-7.24 vs 65.77+/-19.79 years; t-test, P=0.02). Our data suggest that the occurrence of BRAF/N-ras mutations compensate the requirement for the allelic loss at chromosome 9, which is one of the key events in melanoma...
  61. ncbi Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma
    Marcory C R F van Dijk
    Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Am J Surg Pathol 29:1145-51. 2005
    ..Furthermore, we can conclude that mutation analysis may be useful as an additional diagnostic tool to distinguish between benign and malignant spitzoid lesions...
  62. ncbi Rapid mutational analysis of N-ras proto-oncogene in hematologic malignancies: study of 77 Greek patient
    M Speletas
    First Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece
    Haematologica 86:918-27. 2001
    ..Consequently, study of the N-ras oncogene has not been convenient in every day clinical practice being restricted, as a rule, to retrospective analysis of patients...
  63. ncbi Basis for signaling specificity difference between Sos and Ras-GRF guanine nucleotide exchange factors
    X Tian
    Department of Biochemistry, Tufts University School of Medicine, Boston, MA 02111, USA
    J Biol Chem 276:47248-56. 2001
    ..Although previous studies have shown that helix B of Sos1 and helix 3 of Ha-Ras are involved in promoting nucleotide exchange on Ras proteins, this study highlights the importance of these regions in establishing signaling specificity...
  64. ncbi Gene-specific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic exposure to nitrogen mustards
    Vassilis L Souliotis
    National Hellenic Research Foundation, Institute of Biological Research and Biotechnology, Athens, Greece
    Clin Cancer Res 9:4465-74. 2003
    ..To investigate the possibility of measuring the gene-specific DNA damage after therapeutic exposure to nitrogen mustards and to examine its relationship with the clinical response...
  65. pmc Flexibility of ras lipid modifications studied by 2H solid-state NMR and molecular dynamics simulations
    Alexander Vogel
    Junior Research Group Structural Biology of Membrane Proteins, Institute of Biotechnology, Martin Luther University Halle Wittenberg, Halle, Germany
    Biophys J 93:2697-712. 2007
    ..Large motional amplitudes and relatively short correlation times facilitate mixing and dispersal with the lipid bilayer matrix, with implications for the role of the full-length ras protein in signal transduction and oncogenesis...
  66. ncbi Mutations and differential expression of the ras family genes in human nasal polyposis
    Apostolos Zaravinos
    Laboratory of Virology, Medical School, University of Crete, Heraklion 71100, Crete, Greece
    Int J Oncol 31:1051-9. 2007
    ..Our findings suggest a potential key role for activated members of ras family genes in terms of their contribution to the development of NPs as well as to the hypertrophy of adjacent turbinates...
  67. ncbi Transcriptional networks of knockout cell lines identify functional specificities of H-Ras and N-Ras: significant involvement of N-Ras in biotic and defense responses
    E Castellano
    Instituto de Biologia Molecular y Celular del Cancer, Centro de Investigación del Cáncer CSIC USAL, University of Salamanca, Salamanca, Spain
    Oncogene 26:917-33. 2007
    ..Our data support the notion that different Ras isoforms play functionally distinct cellular roles and indicate that N-Ras is significantly involved in immune modulation/host defense and apoptotic responses...
  68. ncbi Transforming genes in duck hepatic carcinoma--mht(raf) and Ha-ras
    H Tan
    Department of Biochemistry and Molecular Biology, Shanghai Cancer Institute
    Sci Sin B 31:1325-32. 1988
    ..2 and 3.2 kb EcoRI fragments) and duck Ha-ras (3.4 kb EcoRI fragments) were present in all these transformants. This is the first report on transforming genes in duck primary hepatic cancer as well as tumor-adjacent liver tissue...
  69. ncbi N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression
    F Basolo
    Dipartimento di Oncologia, University of Pisa, Italy
    Thyroid 10:19-23. 2000
    ..Interestingly, N-ras mutation was restricted to the group of tumours with low or absent thyroglobulin expression, suggesting that this genetic change is prevalent in less differentiated tumors...
  70. ncbi RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia
    J P Perentesis
    Children s Hospital Medical Center, Cincinnati, OH, USA
    Leukemia 18:685-92. 2004
    ..While N- and K-RAS mutations can be identified in 15% of children with newly diagnosed ALL, they do not represent a significant risk factor for outcome using contemporary chemotherapy regimens...
  71. ncbi Selective occurrence of ras mutations in benign and malignant thyroid follicular neoplasms in Taiwan
    Rue Tsuan Liu
    Division of Metabolism, Chang Gung Memorial Hospital, Kaohsiung, Taiwan
    Thyroid 14:616-21. 2004
    ..The selective occurrence of ras mutations in benign and malignant follicular neoplasms indicates that ras gene alterations have a specific and early role in the development of follicular type of thyroid tumors in Taiwan...
  72. doi Modulatory effect of environmental endocrine disruptors on N-ras oncogene expression in the hermaphroditic fish, Kryptolebias marmoratus
    Young Mi Lee
    Department of Chemistry and the National Research Lab of Marine Molecular and Environmental Bioscience, College of Natural Sciences, Hanyang University, Seoul 133 791, South Korea
    Comp Biochem Physiol C Toxicol Pharmacol 147:299-305. 2008
    ..marmoratus may be a suitable model species for oncogene expression studies. The observed EDC-induced expression of N-ras supports the assumption that EDC exposure may predispose the host to the risk of environmental carcinogenesis...
  73. ncbi Mutations in ras proto-oncogenes are associated with lower mdr1 gene expression in adult acute myeloid leukaemia
    M Schaich
    Department of Medicine I, University Hospital Dresden, Germany
    Br J Haematol 112:300-7. 2001
    ..Neither ras mutation nor mdr1 expression had a significant impact on overall or disease-free survival to date. For the first time, there is evidence that activated ras genes are associated with lower mdr1 expression in AML...
  74. ncbi Analysis of single-strand DNA conformation polymorphism by capillary electrophoresis
    H Arakawa
    School of Pharmaceutical Sciences, Showa University, Tokyo, Japan
    J Chromatogr A 722:359-68. 1996
    ..All mutations tested in this study could be distinguished. CE is well suited for clinical analysis of SSCP because it is rapid and reproducible, allows on-line detection and is easy...
  75. pmc Influence of the lipid anchor motif of N-ras on the interaction with lipid membranes: a surface plasmon resonance study
    Andrea Gohlke
    Faculty of Chemistry, Physical Chemistry I Biophysical Chemistry, Technische Universitat Dortmund, Dortmund, Germany
    Biophys J 98:2226-35. 2010
    ..The GDP-bound inactive form of N-Ras with an HD/Far anchor shows stronger membrane association, which might be due to a more pronounced tendency to self-assemble in the membrane matrix than is seen with the active GTP-bound form...
  76. pmc Alpha-fetoprotein stimulated the expression of some oncogenes in human hepatocellular carcinoma Bel 7402 cells
    Meng Sen Li
    Department of Biochemistry, Hainan Medical College, Haikou 571101, China
    World J Gastroenterol 10:819-24. 2004
    ..To investigate the molecular mechanism of alpha-fetoprotein (AFP) on regulating the proliferation of human hepatocellular carcinoma cells...
  77. doi A Proteomic approach for protein-profiling the oncogenic ras induced transformation (H-, K-, and N-Ras) in NIH/3T3 mouse embryonic fibroblasts
    Seyoon Kim
    Department of Biochemistry, Yonsei University, Seoul, Korea
    Proteomics 8:3082-93. 2008
    ..Further studies are in progress to elucidate the implications of these findings in the regulation of Ras induced transformation...
  78. pmc Palmitoylation of oncogenic NRAS is essential for leukemogenesis
    Benjamin Cuiffo
    Rosenstiel Basic Medical Sciences Research Center and Department of Biology, Brandeis University, Waltham, MA, USA
    Blood 115:3598-605. 2010
    Activating mutations of NRAS are common in acute myeloid leukemia, chronic myelomonocytic leukemia, and myelodysplastic syndrome...
  79. ncbi Ras as a therapeutic target in hematologic malignancies
    Yesid Alvarado
    University of Texas MD Anderson Cancer Center, Department of Leukemia, Box 428, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Expert Opin Emerg Drugs 12:271-84. 2007
    ..Here, Ras biology, its signaling pathways and its implications as a therapeutic target in hematologic malignancies are reviewed...
  80. pmc Silencing the expression of Ras family GTPase homologues decreases inflammation and joint destruction in experimental arthritis
    Daphne de Launay
    Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Am J Pathol 177:3010-24. 2010
    ....
  81. pmc Immunohistochemical analysis of p53, cyclinD1, RB1, c-fos and N-ras gene expression in hepatocellular carcinoma in Iran
    S J Moghaddam
    Shaheed Beheshti University of Medical Sciences, Research Center for Gastroenterology and Liver Disease, Tehran 19857, Iran
    World J Gastroenterol 13:588-93. 2007
    ..To study the effect of some genes especially those involved in cell cycle regulation on hepatocellular carcinoma...
  82. ncbi N-ras protein: frequent quantitative and qualitative changes occur in human colorectal carcinomas
    K Kim
    Department of Pathology and Laboratory Medicine, Boston University School of Medicine, MA 02118, USA
    Int J Cancer 71:767-75. 1997
    ....
  83. doi Secondary structure of lipidated Ras bound to a lipid bilayer
    Jörn Güldenhaupt
    Lehrstuhl fur Biophysik, Ruhr Universitat Bochum, Germany
    FEBS J 275:5910-8. 2008
    ..The novel attenuated total reflectance approach opens the way for detailed studies of the interaction network of the membrane-bound Ras protein...
  84. ncbi Mice deficient for N-ras: impaired antiviral immune response and T-cell function
    Ignacio Perez de Castro
    Department of Pathology and Kaplan Comprehensive Cancer Center, New York University School of Medicine, New York, New York 10016, USA
    Cancer Res 63:1615-22. 2003
    ..All of the results derived from this work constitute a significant contribution to the knowledge of N-ras-specific functions...
  85. doi Influence of the lipidation motif on the partitioning and association of N-Ras in model membrane subdomains
    Katrin Weise
    Physical Chemistry I Biophysical Chemistry and Chemical Biology, Faculty of Chemistry, Dortmund University of Technology, Otto Hahn Strabetae 6, D 44227 Dortmund, Germany
    J Am Chem Soc 131:1557-64. 2009
    ..Conversely, the nonbiological dual-hexadecylated N-Ras exhibits a time-independent incorporation into the bulk liquid-disordered phase to maintain high conformational entropy of its lipid chains...
  86. ncbi Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain
    H Adari
    Department of Molecular Biology, Cetus Corporation, Emeryville, CA 94608
    Science 240:518-21. 1988
    ..These results indicate that GAP interaction may be essential for ras p21 biological activity and that it may be a ras effector protein...
  87. doi TCR-induced activation of Ras proceeds at the plasma membrane and requires palmitoylation of N-Ras
    Ignacio Rubio
    Institute for Molecular Cell Biology, Centre for Molecular Biomedicine, University Hospital, Friedrich Schiller University Jena, Jena, Germany
    J Immunol 185:3536-43. 2010
    ..These findings identify the PM as the only site of TCR-driven Ras activation and document that endomembranes are not a signaling platform for Ras in T cells...
  88. ncbi Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure
    Vassilis L Souliotis
    National Hellenic Research Foundation, Institute of Biological Research and Biotechnology, 48 Vassileos Constantinou Ave, Athens 11635, Greece
    DNA Repair (Amst) 5:972-85. 2006
    ..To conclude, the in vivo gene-specific repair of melphalan-induced damage in humans is greatly affected by the local chromatin structure...
  89. ncbi Molecular genetic aspects of myelodysplastic syndromes
    C R Bartram
    Department of Pediatrics II, University of Ulm, Germany
    Hematol Oncol Clin North Am 6:557-70. 1992
    ..However, the clinical relevance of molecularly defined parameters has already been established for their use as clonal markers in determining the mode of action and efficiency of different therapeutic approaches...
  90. ncbi Needle-in-a-haystack detection and identification of base substitution mutations in human tissues
    V L Wilson
    Institute of Environmental Studies, Louisiana State University, Baton Rouge, LA 70803, USA
    Mutat Res 406:79-100. 1999
    ....
  91. ncbi N-ras mutations in myeloid leukemias
    G Saglio
    , Italy
    Tumori 75:337-40. 1989
    ..These data suggest that a partial overlapping between initiation and progression factors could exist in naturally occurring tumors...
  92. ncbi Effects of melatonin on mammary gland lesions in transgenic mice overexpressing N-ras proto-oncogene
    M D Mediavilla
    Department of Physiology and Pharmacology, School of Medicine, University of Cantabria, Santander, Spain
    J Pineal Res 22:86-94. 1997
    ....
  93. ncbi Molecular analysis of rat embryo cell transformants induced by alpha-particles
    B Endlich
    Laboratory of Radiation Biophysics, Memorial Sloan Kettering Cancer Center, New York, NY 10021
    Int J Radiat Biol 64:715-26. 1993
    ....
  94. ncbi BRAF mutations are common somatic events in melanocytic nevi
    Rajiv Kumar
    Division of Molecular Genetic Epidemiology, German Cancer Research Center DKFZ, Heidelberg, Germany
    J Invest Dermatol 122:342-8. 2004
    ..We hypothesize the dual effect of solar ultraviolet irradiation on melanoma, through mutagenesis and by increasing the number of melanocytic nevi, many of which carry a BRAF or N-ras mutation...
  95. doi Considerations for licensure of influenza vaccines with pandemic and prepandemic indications
    Norman W Baylor
    FDA CBER OVRR, HFM 405, 1401 Rockville Pike, Rockville, MD 20852, USA
    Curr Top Microbiol Immunol 333:453-70. 2009
    ..The Food and Drug Administration (FDA) along with other national regulatory authorities (NRAs) recognize the important role that safe and effective vaccines will play in protecting the public health from the ..
  96. pmc Saccharomyces cerevisiae cdc15 mutants arrested at a late stage in anaphase are rescued by Xenopus cDNAs encoding N-ras or a protein with beta-transducin repeats
    W Spevak
    Ernst Boehringer Institute, Vienna, Austria
    Mol Cell Biol 13:4953-66. 1993
    ..In this region, beta Trcp is composed of seven beta-transducin repeats. beta TrCP is not a functional homolog of S. cerevisiae CDC20, a cell cycle gene that also contains beta-transducin repeats and suppresses the cdc15 mutation...
  97. ncbi Sustained activation of M-Ras induced by nerve growth factor is essential for neuronal differentiation of PC12 cells
    Peng Sun
    Department of Biology, Faculty of Science, and Graduate School of Science and Technology, Chiba University, Yayoicho, Inageku, Chiba, Chiba 263 8522, Japan
    Genes Cells 11:1097-113. 2006
    ..Therefore, M-Ras is essential for neuronal differentiation in PC12 cells by inducing sustained activation of ERK pathway...
  98. pmc Structure of the 1,4-Bis(2'-deoxyadenosin-N(6)-yl)-2S,3S-butanediol intrastrand DNA cross-link arising from butadiene diepoxide in the human N-ras codon 61 sequence
    Wen Xu
    Department of Chemistry, Center in Molecular Toxicology, Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee 37235, USA
    Chem Res Toxicol 20:187-98. 2007
    ..Nechev, L. V., Tamura, P. J., Harris, C. M., Harris, T. M., and Lloyd, R. S. (2002) Chem. Res. Toxicol. 15, 1572-1580)...
  99. ncbi Purification, characterization, and western blot analysis of human GTPase-activating protein from native and recombinant sources
    R Halenbeck
    Department of Protein Chemistry, Cetus Corporation, Emeryville, California 94608
    J Biol Chem 265:21922-8. 1990
    ..Type I and II GAP species were detected in approximately equal amounts in cytoplasmic extracts of human placenta, but only type I GAP was observed when other human tissues were examined...
  100. pmc Alteration of homeobox gene expression by N-ras transformation of PA-1 human teratocarcinoma cells
    R Buettner
    Department of Tumor Biology, University of Texas M D Anderson Cancer Center, Houston 77030
    Mol Cell Biol 11:3573-83. 1991
    ..We conclude that stimulation of a putative growth factor signal pathway, associated with ras-induced proliferation, transiently suppresses the induction of transcription factors functionally involved in cell growth and differentiation...

Research Grants63

  1. Rutao Cui; Fiscal Year: 2014
    ..Expanding our knowledge of DNA repair in different skin types provides a rich ground for melanoma prevention and for the development of targeted small-molecule therapeutics. ..
  2. The Unfolded Protein Response in Melanoma Progression and Chemoresistance
    Maria S Soengas; Fiscal Year: 2012
    ..benign melanocytic neoplasms (nevi) expressing pro- oncogenic mutations in the MAPK pathway, usually in the BRAF or NRAS genes. Still, these mutated nevus cells can remain mitotically inactive for decades...
  3. Jeffrey W Smith; Fiscal Year: 2016
    ..abstract_text> ..
  4. DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE LEUKEMIA
    Jerry Radich; Fiscal Year: 1993
    ..In sum, this proposal could broaden the understanding of the biology of leukemia, aid in its therapy, and provide support to an emerging clinical scientific career...
  5. Genetic and genomic analysis of Ras signaling in colorectal cancer progression
    KEVIN MICHAEL HAIGIS; Fiscal Year: 2010
    ..Through my functional studies of the K-RAS oncogene, I aim to identify molecular targets for novel therapeutics that will eradicate colon cancer. ..
  6. BONNIE ELYSSA GOULDROTHBERG; Fiscal Year: 2014
    ..Thomas Lynch as Physician-in-Chief of the new cancer hospital. ..
  7. Compartment Specific Signaling of Ras
    MARK REID PHILIPS; Fiscal Year: 2010
    ....
  8. Sheri L Holmen; Fiscal Year: 2016
    ..the dopachrome tautomerase (DCT) promoter and propose to utilize retroviral vectors containing Cre-recombinase and NRas(Q61R) to induce melanoma in DCJ-T\/A/lnk4a/Arf l[unreadable]*/l[unreadable]* mice...
  9. TRANSCRIPTIONAL INTERFERENCE AND TUMORIGENICITY
    Perry Kannan; Fiscal Year: 2000
    ..Abolition of AP-2 transcriptional self-interference using coactivators might reverse tumorigenicity of PA-1 cells induced by RAS oncogene and that would clearly establish the clinical importance of transcriptional coactivators. ..
  10. Preeti Tandon; Fiscal Year: 2014
    ..The overall goal of this research is to delineate the functions of Ras proteins in NF1 pathogenesis and to identify novel therapeutic strategies based on inhibition of specific Ras proteins. ..
  11. Blood-based detection of BRAF and NRAS DNA as biomarkers in patients with stage I
    David Polsky; Fiscal Year: 2013
    ..abstract_text> ..
  12. Boris C Bastian; Fiscal Year: 2016
    ..MAP) kinase pathway is a common feature in uveal melanoma, mutations in known melanoma oncogenes such as BRAF, NRAS, or KIT are absent...
  13. Feng Liu-Smith; Fiscal Year: 2016
    ..1A), as well as mechanistic study of how these variants affect the cellular ROS levels, UV-induced DNA damage and NRAS oncogene activation (Aim 1B)...
  14. The role of c-Met expression in melanoma growth and migration
    AMBER LEIGH SHADA; Fiscal Year: 2010
    ..of varying genetic background, evaluation of the downstream signaling mechanism in the setting of BRAF and NRAS mutations, and preclinical studies of HGF and c-Met blockade in a mouse xenograft model of human melanoma...
  15. Ha Linh Vu; Fiscal Year: 2016
    ..This project focuses on the signaling pathways in NRAS mutant melanomas, which accounts for approximately 20% of melanomas...
  16. Molecular signatures of melanoma histology and progression: A Population Based A
    Abrar A Qureshi; Fiscal Year: 2013
    ..platform with over 6000 genes and a Sequonome platform to sequence MC1R and genotype specific loci for BRAF and NRAS to: a...
  17. MOLECULAR GENETICS OF MOUSE LUNG TUMORS
    Ming You; Fiscal Year: 2009
    ..abstract_text> ..
  18. MIKHAIL NIKIFOROV; Fiscal Year: 2016
    ..Activating amino acid substitutions in oncoproteins BRAF (V600E) and NRAS (Q61R) have been found in approximately 60% and 20% of melanomas, respectively...
  19. ATF2 in melanoma development and progression
    ZE apos EV A RONAI; Fiscal Year: 2012
    ..Our proposed studies will extend the use of relevant mouse melanoma models to assess ATF2 role in melanoma development and to identify and characterize the mechanisms underlying ATF2 role in the development of this tumor type. ..
  20. Repair of Clustered DNA Damages
    Yoke W Kow; Fiscal Year: 2010
    ..In addition, it will provide significant insight as to the potential mechanism involved in melanoma progression. ..
  21. Christopher M Counter; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): KRAS, to a lesser extent NRAS, and rarely HRAS, are mutated in a third of human cancers, which is well established to promote tumorigenesis...
  22. The role of ultraviolet radiation and skin pigmentation in melanoma development
    Devarati Mitra; Fiscal Year: 2013
    ..a novel melanoma mouse model, red/blond, albino, and black mice which also carry an activatable form of BRAF or NRAS (the most commonly mutated oncogenes in melanoma) are being generated...
  23. Farrukh Afaq; Fiscal Year: 2014
    ..have constitutively active mitogen activated protein kinases (MAPK) through oncogenic mutation in either BRAF or NRAS. In malignant melanoma the BRAF-MEK-ERK and PI3K-AKT-NFkB signaling pathways are constitutively activated and ..
  24. Nancy E Thomas; Fiscal Year: 2014
    ..variations in chemokines and their receptors and determine their associations with melanoma risk, survival, and NRAS and BRAF mutational subtypes in the large international population-based Genes, Environment, and Melanoma (GEM) ..
  25. Diagnosing Emergence of Kinase Inhibitor Resistance on a Microchip
    Thomas G Graeber; Fiscal Year: 2013
    ..Graeber, H.-R. Tseng, R. Lo and A. Ribas), make the melanoma microfluidic diagnostic approach uniquely positioned to impact ongoing clinical trials and therapy. ..
  26. Ze ev A Ronai; Fiscal Year: 2015
    ..Lastly, we will use a high- content screen, already established, to identify natural compounds that promote nuclear export of ATF2 in melanoma cells, thereby offering a novel therapeutic modality for melanoma. ..
  27. Jessie Villanueva; Fiscal Year: 2016
    ..for melanoma patients by investigating the mechanisms of intrinsic resistance to targeted therapy in BRAF-V600E and NRAS mutant melanomas...
  28. CHELSEA SCHWARTZ PLACE; Fiscal Year: 2014
    ..Mutant NRAS represents one well-known cytoplasmic GTPase in this setting...
  29. GAB2 in metastatic melanoma
    Julide T Celebi; Fiscal Year: 2013
    ..genetic event amplified in a subset of acral and mucosal melanomas independent of genetic alterations in BRAF, NRAS, and KIT...
  30. Ze ev A Ronai; Fiscal Year: 2015
    ..We therefore propose to: (i) substantiate these initial observations in Nras and Braf mutan melanoma harboring WT Pten-models representing the vast majority of human melanomas, (ii) ..
  31. Uses of GEM models for Translational Cancer Research
    Lynda Chin; Fiscal Year: 2013
    ..In Program 1, inducible NRAS* metastatic melanoma model and a high metastatic PTEN/SMAD4 prostate cancer model will be engineered to experience ..
  32. MEENHARD F HERLYN; Fiscal Year: 2015
    ..Mutations are most frequent in BRAF (50%) followed by NRAS (15%) and c-kit (4%). 2) Within each mutation group there are sub-groups due to additional critical mutations...
  33. Ras signaling in leukemogenesis
    Ruibao Ren; Fiscal Year: 2010
    ..The ultimate goal of these studies is to identify critical molecular events in Ras leukemogenesis, allowing therapeutic interventions of leukemias involving Ras. ..
  34. Ras Peptide Aptamers
    WILSON XU; Fiscal Year: 2009
    ..2. Peptide aptamers that interact with oncogenic Ras. 3. Peptide aptamers that inhibit tumorigenesis. These studies provide a new systematic framework for developing inhibitors of any proteins of biological and/or medical importance. ..
  35. BENJAMIN BRAUN; Fiscal Year: 2016
    ..Somatic NRAS and KRAS mutations are common in MDS/MPN, and mice that express an activated KrasD12 allele develop a similar ..
  36. DNA/RNA G-Quadruplexes: Structures, Transitions and Recognition
    Dinshaw J Patel; Fiscal Year: 2013
    ....
  37. JOE WILLIAM RAMOS; Fiscal Year: 2015
    ..Moreover, the findings derived from this proposal should also contribute to advance our understanding of Ras signaling pathways beyond skin carcinogenesis, and may have applications to other systems where RasGRP1 is also expressed. ..
  38. STEVEN P O'HARA; Fiscal Year: 2015
    ..We propose that this signaling pathway promotes cholangiocyte inflammatory responses, which promotes the attraction of leukocytes to the portal tract. ..
  39. Inorganic phosphate regulated proliferation, transformation and tumorigenesis
    George R Beck; Fiscal Year: 2013
    ..This proposal will investigate the role of dietary inorganic phosphate in cancer initiation, promotion and progression. ..
  40. Histone Deacetylase Inhibitor Based Therapy of AML
    Kapil Bhalla; Fiscal Year: 2011
    ..The proposed pre-clinical studies could potentially define HAA-HDI based novel combinations and generate the rationale to test their in vivo efficacy against human AML cells. ..
  41. Jing Zhang; Fiscal Year: 2015
    ..Oncogenic NRAS mutations, which are among the most frequently identified genetic mutations in myeloid diseases, are identified in ..
  42. Dan A Liebermann; Fiscal Year: 2016
    ....
  43. Kevin M Shannon; Fiscal Year: 2016
    ..project, we will exploit transplantable primary myeloid and lymphoid leukemias from strains of Nf1 mutant and Kras/Nras "knock in" mice that accurately model human cancers as a controlled evolutionary system and experimental platform ..
  44. Cooperative of Hras or Braf wiht Pten in Thyroid Carcinogenesis
    Aime T Franco; Fiscal Year: 2010
    ..of non-overlapping mutations of the genes encoding the receptor tyrosine kinases RET and TRK, as well as of NRAS, HRAS, KRAS and BRAF...
  45. Bypassing Oncogene Addiction: Mechanisms of off-target resistance in CML
    GABRIEL ANTHONY REYES; Fiscal Year: 2013
    ..persistent MAPK and JAK/STAT signaling despite BCR-ABL inhibition, we have identified the presence of activating NRAS mutations in conjunction with EVI-1 overexpression...
  46. Flexible and Somatic Mouse Models for Myelodysplastic Syndrome Progression
    Yupo Ma; Fiscal Year: 2009
    ..and AML transformation through the somatic delivery of avian retroviruses that encode hyperactive KRAS and NRAS to transgenic mice...
  47. Forest M White; Fiscal Year: 2014
    ..These include Noonan Syndrome (NS), caused by PTPN11, SOS1, KRAS, NRAS, SHOC2 or RAF1 mutations, LEOPARD syndrome (LS), caused by PTPN11 mutations, Costello Syndrome (CS), caused by HRAS ..
  48. James C Mulloy; Fiscal Year: 2014
    ..This high-risk/high-yield project is based on solid experimental approaches developed in my lab and has great potential for high impact findings with rapid translation to the clinic. ..
  49. The Role of Oncogenic Ras in Leukemogenesis and Response to Targeted Therapies
    Qing Li; Fiscal Year: 2012
    ..Studies of human leukemia samples have shown that NRAS and KRAS2 point mutations, the BCR-ABL fusion, PTPN11 mutations, FLT3 internal tandem duplications, and NF1 ..
  50. SBIR TOPIC 294 PHASE I - DEVELOPMENT OF GLYCOSYLATION-SPECIFIC RESEARCH REAGENTS
    Hyesook Kim; Fiscal Year: 2011
    ..abstract_text> ..
  51. In Vivo Analysis of Oncogenic Kras in Leukemogenesis
    BENJAMIN BRAUN; Fiscal Year: 2009
    ..Activating mutations in the HRAS, KRAS, and NRAS genes are the most common oncogenic lesions found in human cancer and are detected in approximately 30% of patients ..
  52. Qing Lin; Fiscal Year: 2016
    ..We will examine the effect of chemical phosphorylation on the engineered STAT-1 dimerization, nuclear transport, and transcriptional activation in living cells. ..
  53. Jing Zhang; Fiscal Year: 2016
    ..conditional mouse models of human myeloproliferative diseases (MPDs) that express one or two copies of oncogenic Nras in the hematopoietic compartment (Nras G12D/+ and Nras G12D/G12D), respectively...
  54. Targeting Ras-Dependent Cancers with a Chemical Switch for an Inactive Kinase
    ARVIN DAR; Fiscal Year: 2013
    ....
  55. REGULATION OF APOPTOSIS BY CELLULAR RAS ISOFORMS
    Alan Wolfman; Fiscal Year: 2003
    ..abstract_text> ..
  56. Kevin M Shannon; Fiscal Year: 2016
    ..Ras) family of signal switch proteins is deregulated in myeloid malignancies by genetic mechanisms that include NRAS and KF^S2 point mutations, the BCR-ABL fusion, PTPN11 mutations, and NF1 inactivation...
  57. GENETIC ANALYSIS OF CHARCOT-MARIE-TOOTH DISEASE
    PHILLIP CHANCE; Fiscal Year: 1992
    ..A regional gene linkage map of chromosome 1 is of general scientific interest and will provide a useful tool to study many human disorders in this region...
  58. Brent R Stockwell; Fiscal Year: 2014
    ..This project could thus lead to the first small molecule therapeutics for targeting tumors with mutant K-Ras and may open up a large number of undruggable targets to small molecule inhibition. ..
  59. CLONALITY IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASIA
    Donald Kufe; Fiscal Year: 1992
    ..Such information could lead to improved prognostic data as well as more effectively timed therapeutic interventions...
  60. In vivo systems biology of inflammatory response in the intestinal epithelium
    Douglas A Lauffenburger; Fiscal Year: 2012
    ..In the end, these studies will broaden our knowledge of the molecular pathways that contribute to IBD and may have a direct impact on the health and well being of many patients suffering from this terrible disease. ..
  61. Regio/stereochem defined, diol epoxide adducted ras
    MAHESH LAKSHMAN; Fiscal Year: 2001
    ..The PI will also collaborate with other groups and the topics to be addressed are (a) NMR analyses, (b) possibly x-ray structures, (c) mutation analyses, (d) DNA repair, and (e) fluorescence studies. ..
  62. CAAX Processing Enzymes as Anticancer Targets
    Stephen Young; Fiscal Year: 2005
    ..Using these mice, we will define the impact of defective CAAX processing on the development, progression, and lethality of Ras-induced myeloproliferative disease. ..
  63. ETIOLOGY OF ESTROGEN INDUCED PROLACTIN TUMORS
    Richard Weiner; Fiscal Year: 1991
    ..These studies will increase our understanding of the mechanisms and cellular sites of action of E2 in tumor formation. Studies with 16K PRL could lead to the development of a new class of angiolytic drugs for treatment of cancer...